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10 Oral Presentationstransplantation (HCT). Therapeutic administration of corticoste-
roids is often required after HCT to treat acute and chronic graft
versus host disease (GVHD). Although corticosteroids are known
to induce T-cell apoptosis and suppress T-cell cytotoxic function,
their effects on NK cells have not been well characterized. We in-
vestigated for differences between T cells and ex vivo expanded NK
cells in their susceptibility to apoptosis and inhibition of prolifera-
tion following treatment with corticosteroids. T and NK cells were
isolated by magnetic bead separation from peripheral blood mono-
nuclear cells. NK cells were expanded in X-vivo 20 with 10%
human AB serum, 500U/ml IL-2 and irradiated (100Gy) Epstein-
Barr virus transformed B cells for 7 days. T cells were expanded
for 5 days in RPMI 1640 supplemented with IL-2. Hydrocortisone
was used in vitro at concentrations (0.5ug/mL to 20ug/mL) compa-
rable to drug levels achieved in patients receiving 1mg/kg to 1 gram
of methylprednisolone . Apoptosis, cellular proliferation and the
cytolytic function of T and NK cells against K562 cells were eval-
uated by flow cytometry staining for annexin-V and 7-AAD, thymi-
dine incorporation and 51Cr-release assays respectively. Compared
to T-cells, NK cells were resistant to the apoptotic and anti-prolif-
erative effects of hydrocortisone; hydrocortisone concentrations of
0.5ug/ml and 20ug/mL inhibited T-cell proliferation by 60% (p5
0.005) and 80% (p 5 0.001) respectively, whereas steroids at these
same doses did not inhibit NK cell proliferation (table). In contrast
to T-cells, NK cells were resistant to steroid-induced apoptosis; at
steroid concentration of 20ug/mL 81% of T cells (grown in serum
free media) stained positive for annexin-V versus 42% of NK cells
(table). NK cell cytolytic function against K562 targets was not af-
fected by steroid exposure; at an NK cell: K562 ratio of 1:1, NK
cells treated with 0, 0.5ug/ml, and 20ug/ml of hydrocortisone lysed
35%, 33%, and 27% of K562 targets respectively (p 5 n.s.). These
findings show that NK cells are resistant to the immunosuppressive
effects of corticosteroids compared to T-cells and further suggest
that corticosteroid administration following allogeneic HCT may
not preclude a beneficial anti-tumor effect of adoptively infused
donor NK cells.
Steroid Effect on Apoptosis and Proliferation of Tand NK cells
Steroid %T cell % NK cell T NK
Concentration Apoptosis Apoptosis P cell SI* cell SI* P0 ug/mL 73% 45% 1 1
0.5 ug/mL 77% 40% 0.009 0.4 1.07 0.004
20 ug/mL 81% 42% 0.02 0.16 0.98 0.005
200 ug/mL 95% 38% 0.06 0.01 0.69 0.05SI*. Stimulation Index.20
IN SITU ACTIVATION OF HOST CD41 CD251 FOXP31 T CELLS: A NEW
STRATEGYFORCIRCUMVENTINGRESISTANCEANDESTABLISHMENTOFHE-
MATOPOIETIC ENGRAFTMENT AFTER MHC-MATCHED ALLOGENEIC HCT
Shatry, A., Levy, R.B. University of Miami Miller School of Medicine,
Miami, FL
Treg infusions have been shown to suppress HVG and GVH in
experimental allogeneic HCT. These findings have engendered
enthusiasm for the administration of Tregs in the clinical setting.
We hypothesized that activation/expansion of Tregs in situ may
represent an approach that obviates the requirement to isolate
and enrich Treg populations for use in such transplants. To ad-
dress this question, we administered a complex of IL-2 and
anti-IL2 mAb (IAC) to recipients following reduced intensity
conditioning (RIC) and allogeneic MHC-matched HCT. A pro-
tocol was identified which significantly enhanced early donor chi-
merism, and importantly, facilitated long-term multi-lineage
engraftment in these recipients. Administration of this complex
relative to the time of HCT was crucial: post-HCT treatment
with IAC more efficiently facilitated marrow engraftment com-
pared to pre-HCT administration. Donor chimerism remained
present .27 weeks post-HCT. One week post-HCT, the fre-
quency of host Tregs as well as CD25 expression (MFI) were sig-
nificantly elevated in IAC-treated vs. control recipients. Toaddress a potential mechanism for these observations, we assessed
host-anti-donor (tetramer1) CD8 T cells that arise post-HCT
and mediate resistance to engraftment. IAC but not control
(PBS) treatment suppressed the emergence of these host tet-
ramer1 expressing CD8 T cells early post-HCT. Following in
vivo administration of donor antigen into chimeric and non-
chimeric recipients .6 months post-HCT, an increased
frequency of tetramer1 CD8 cells was observed only in non-
chimeric marrow allograft recipients. Importantly, LPS and
anti-CD3 responses by splenocytes from both groups of recipi-
ents were comparable. Hence, we conclude that the inhibition
of host anti-donor reactive CD8 cells was not associated with
global immune suppression in chimeric animals and may indicate
tolerance in these recipients. In total, these findings are consis-
tent with the notion that the transient activation/expansion of
host Tregs in situ post-HCT can be explored as a new strategy
to regulate host alloreactivity post-transplant. Notably, the in
situ stimulation of recipient Tregs following RIC obviated the in-
fusion of Tregs and may represent an alternative approach to,
and/or complement – the adaptive transfer of Treg populations
in clinical HCT.21
PRE-TRANSPLANT RISK ASSESSMENT IN ADULT ACUTE LYMPHOCYTIC
LEUKEMIA
Terwey, T.H.1, Massenkeil, G.2, le Coutre, P.1, Hemmati, P.1,
Neuburger, S.1, Dorken, B.1, Arnold, R.1 1Charite, Campus
Virchow-Klinikum, Berlin, Germany; 2Gu¨tersloh General Hospital, Gu¨-
tersloh, Germany
Introduction: Hematopoietic cell transplantation (HCT) can
be curative in hematological malignancies but the procedure is
associated with significant risks. Several scoring systems have
been developed to predict transplant-related mortality (TRM)
and overall survival (OS), however none has become a standard
in clinical decision making yet. In the present study we compared
the prognostic value of the HCT Comorbidity Index (HCT-CI)
(Sorror ML, Blood 2005), the Pretransplantation Assessment of
Mortality score (PAM) (Parimon T, Ann Intern Med 2006), the
EBMT risk score (ERS) (Gratwohl A, Lancet 1998) and the Kar-
nofky-Index (KI) in 151 adult patients who received HCT for
acute lymphocytic leukemia (ALL) from 1995 until 2007 at our
center.
Methods: Risk scores were calculated as defined in the original
publications based on data extracted from patient charts, dis-
charge letters and computer databases. Median age was 31 years
(16–67). Disease status was first complete remission (CR) (n 5
72), higher CR (n 5 31) and no CR (n 5 48). Patients received
high-dose (HD) (n 5 138) or reduced intensity conditioning
(RIC) (n 5 13) and bone marrow (n 5 41) or peripheral blood
stem cells (n 5 110) from related (n 5 63) or unrelated (n 5 88)
donors. Graft-versus-host-disease (GVHD) prophylaxis was
CSA/MTX for HD or CSA/MMF for RIC. OS was assessed by
Kaplan-Meier curves and logrank statistics, cumulative incidence
of relapse mortality and NRM was assessed by competitive risk
analysis.
Results:Median follow-up was 48 months (5–144). OS at 1, 3
and 5 years was 62% (55–69), 45% (37–54) and 40% (31–49).
Deaths were due to relapse (n 5 47), GVHD (n 5 15), infections
(n 5 17) or other causes (n 5 8). According to HCT-CI criteria
comorbid conditions were present in 98 patients with liver dis-
ease (n 5 43), lung disease (n 5 34) and infections (n5 34) being
the most common. Median scores for HCT-CI, PAM, ERS and
KI were 1 (0–10), 24 (15–36), 3 (0–6) and 90% (60–100), respec-
tively. We found that the HCT-CI and PAM were not predictive
for OS or NRM whereas the EBMT risk score and KI were able
to predict outcome based on differences in relapse mortality
(Table 1).
Conclusions: 65% of ALL patients undergoing HCT at our cen-
ter had significant pre-transplant comorbidities as assessed byHCT-
CI criteria. ERS and KI had discriminative potential for OS and re-
lapse incidence, however prediction of NRM was not possible with
the examined indices. Further research is needed to optimize risk
assessment in ALL patients.
Oral Presentations 11EBMT risk score and Karnofsky index predict OS and relapse
mortality
CumulativeProjected
5-year OS PCumulative
2-year NRM P5-year
relapse
mortality PHCT-CI low 43% (29-58) NS 25% (14-37) NS 29% (17-42) NS
HCT-CI
intermediate
38% (35-50) 18% (10-29) 37% (25-49)HCT-CI high 40% (21-59) 26% (12-43) 34% (16-53)
PAM
category
11242% (27-59) NS 16% (7-28) NS 35% (20-50) NSPAM
category
31439% (29-49) 25% (17-33) 33% (24-42)ERS\ 3 59% (42-73) 0.0002 20% (10-33) NS 20% (10-33) 0.0172
ERS 5 3 43%(26-61) 22% (10-29) 34% (19-50)
ERS . 3 20% (9-32) 33% (23-50) 44% (30-57)
KI 100% 51% (39-64) 0.0162 20% (15-34) NS 23% (14-34) 0.0163
KI\5 90% 29% (18-41) 24% (11-30) 44% (31-55)PAM and ERS were grouped according to similar 5-year OS.AUTOLOGOUS
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COMPARISON OF GRAFT DURABILITY AMONG LYMPHOMA PATIENTS
WHO RECEIVED PLERIXAFOR IN COMBINATION WITH G-CSF FOR PRI-
MARY VERSUS FAILED MOBILIZATION
Micallef, I.N.M.1, Stiff, P.J.2, DiPersio, J.F.3, Maziarz, R.T.4,
McCarty, J.M.5, Angell, J.6, Bridger, G.6, Calandra, G.6 1Mayo Clinic,
Rochester, MN; 2Loyola University, Chicago, IL; 3Washington University
School of Medicine, Saint Louis, MO; 4Oregon Health & Science Univer-
sity, Portland, OR; 5Virgina Commonwealth University Medical Center,
Richmond, VA; 6Genzyme Corporation, Cambridge, MA
Introduction: The addition of plerixafor to G-CSF (P 1 G)
successfully mobilizes sufficient hemtopoietic stem cells (HSC) for
autologous stem cell transplantion (ASCT) in patients with non-
Hodgkin’s lymphoma (NHL). In this analysis, we compare 12-
month graft durability among NHL patients receiving P 1 G as
a front-line or rescue mobilization regimen.
Methodology:Patients enrolled in the Phase III study who failed
to mobilize $2  106 CD341 cells/kg could enter into the rescue
arm of the study and receive P 1 G. Following a rest period of $7
days, patients were re-mobilized with G-CSF (10 mcg/kg/day) for
four days, and on the evening of day four, plerixafor (240 mcg/kg
SQ) was administered. On day five, all patients received a morning
dose of G-CSF before apheresis. The apheresis was a 3 volume 6
10% apheresis. Patients continued to receive P 1 G followed by
daily apheresis for up to four days or until $5  106 CD341
cells/kg were collected. Graft durability was measured at 3, 6 and
12 months; grafts were considered durable if at least 2 of the 3 fol-
lowing criteria were met: platelet count .50,000/ml without trans-
fusion for at least 2 weeks prior to follow-up, hemoglobin level$ 10
g/dL with no erythropoietin support or transfusions for at least 1
month before follow-up, absolute neutrophil count .1,000/ml
with no G-CSF for at least 1 week before follow-up visit. Patients
who had disease progression or died with a stable graft were
censored.
Results: As reported before, 130/150 (87%) patients receiving
P 1 G as a front-line regimen and 37/62 (60%) receiving P 1 G
as a rescue regimen collected $2  106 CD341 cells/kg. 135 pa-
tients in the front-line group and 52 patients in the rescue group un-
derwent ASCT. Data to evaluate graft durability at 12-months were
available for 112/135 (83%) patients in the front-line group and
44/52 (85%) patients in the rescue group. At 12-months, the propor-
tion of patients that maintained a durable graft in the front-line
group was 98.2%. One patient had graft failure due to pre-existing
myelodysplastic syndrome and one patient had AML. Compara-
tively, based on laboratory and clinical criteria, 100% of rescue
patients maintained a durable graft at 12-months.Conclusion: These data demonstrate that the quality of the HSC
collected with P 1 G in the rescue arm resulted in graft durability
rates that were comparable to cells transplanted when P 1 G was
used as a front-line mobilization regimen among patients with
NHL.23
TREATMENT-RELATEDMORTALITY IN PATIENTSWITH AL AMYLOIDOSIS
UNDERGOING HIGH-DOSE MELPHALAN AND STEM CELL TRANSPLANTA-
TION: TREND OVER THE PAST 14 YEARS AT A SINGLE INSTITUTION
Sanchorawala, V., Skinner, M., Finn, K.T., Quillen, K., Seldin, D.C.
Boston University Medical Center, Boston, MA
AL amyloidosis is caused by a clonal plasma cell dyscrasia leading
to multisystem organ failure and death. Aggressive treatment of AL
amyloidosis with high dose intravenous melphalan followed by
autologous stem cell transplantation (HDM/SCT) is effective in
inducing hematologic remissions and in extending survival. How-
ever, HDM/SCT is a challenging treatment for patients with AL
amyloidosis, given their multisystem disease. Morbidity and mor-
tality are associated with all phases of HDM/SCT: during stem
cell mobilization and collection, during post-treatment myelosup-
pression, and following hematopoietic engraftment. Between 7/94
and 7/08, 496 HDM/SCT were performed for patients with AL
amyloidosis, (median age5 56, range 28–80), at Boston University
Medical Center. Treatment-related mortality is defined as deaths
during stem cell mobilization and collection (SCMC) phase as
well as within 100 days after SCT. Overall treatment-related mor-
tality was 12% (58/496). Of the 58 deaths, 11 (2%) occurred during
the stem cell mobilization and collection phase of treatment, while
47 (9%) occurred within 100 days after SCT. Deaths during SCMC
were associated with arrhythmia (n 5 1), irreversible congestive
heart failure (n 5 2), refractory hypotension (n 5 3), myocardial
infarction due to small vessel amyloid disease (n 5 1), GI bleeding
(n5 3) and pulmonary embolism (n5 1). There were 5 deaths dur-
ing the stem cell infusion procedure. There were additional 42
deaths fromD1 1 toD1 100 after SCT.Deaths during this period
were associated with sepsis (33%), cardiac arrhythmia (26%) and
bleeding complications (10%). Overall treatment-related mortality
was 14% (52/371) during the period from 7/94 to 7/04, the first de-
cade of HDM/SCT for patients with AL amyloidosis. However,
overall treatment-related mortality has improved to 5% (6/125)
during the period from 8/04 to 7/08. Improvement in treatment-re-
lated mortality rate over the past 14 years may be due to improved
patient selection, to improvement in supportive care and to the cu-
mulative experience of the treating multidisciplinary team mem-
bers. In summary, HDM/SCT in AL amyloidosis presents unique
challenges. Both clinicians and patients must be prepared for
both the usual and unusual toxicities that may occur. Treatment-re-
lated mortality can be expected to be greater at centers with limited
experience with HDM/SCT for AL amyloidosis, compared with
centers that focus on this complex disease.GRAFT PROCESSING
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EX VIVO EXPANSION OF HUMAN CORD BLOOD PROGENITOR CELLS
WITH THE NOTCH LIGANDDELTA1 RESULTS IN RAPIDMYELOID RECON-
STITUTION IN VIVO FOLLOWINGMYELOABLATIVE CORD BLOOD TRANS-
PLANTATION
Delaney, C.1,2, Brashem-Stein, C.1, Voorhies, H.1, Gutman, J.1,3,
Heimfeld, S.1, Bernstein, I.D.1,2 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2University of Washington School of Medicine, Seattle,
WA; 3University of Washington School of Medicine, Seattle, WA
We herein report results of the first 8 patients with leukemia en-
rolled in a phase I study evaluating the safety and potential efficacy
of cord blood (CB) progenitors cultured in the presence of the
Notch ligand, Delta1. Following a myeloablative preparative reg-
imen, patients received a CBU followed by a second unit that was
expanded ex vivo. Median age and weight of the patients enrolled
is 26 years (range 3 to 43) and 53 kg (16 to 76). After culture, the
average CD34 fold increase was 135 (41 to 382) with an average
total nucleated cell (TNC) fold increase of 570 (146 to 1496).
